DEPENDENCE OF PHARMACOKINETICS AND HEPATOTOXIC ACTION OF ISONIAZID ON ITS ACETYLATION RATE IN PATIENTS WITH DRUG-SENSITIVE PULMONARY TUBERCULOSIS
- Авторлар: Krasnova N.M.1, Nikolaev V.M.2, Efremova E.N.3, Egorova A.A.3, Tatarinova T.E.4, Maksimova N.E.4, Prokopiev E.S.3, Kravchenko A.F.3, Tatarinova O.V.4, Vengerovsky A.I.5, Sychev D.A.6
-
Мекемелер:
- M.K. Ammosov North-Eastern Federal University
- Yakutsk Scientific Center for Complex Medical Problems
- E.N. Andreev Phthisiology Research and Practice Center
- Republican Clinical Hospital No. 3
- Siberian State Medical University of the Ministry of Healthcare
- Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare
- Шығарылым: Том 8, № 4 (2022)
- Беттер: 41-48
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/288996
- DOI: https://doi.org/10.18565/therapy.2022.4.41-48
- ID: 288996
Дәйексөз келтіру
Аннотация
Толық мәтін
![Рұқсат жабық](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Авторлар туралы
Natalia Krasnova
M.K. Ammosov North-Eastern Federal University
Email: krasnova14@mail.ru
PhD in Medicine, associate professor of the Department «Hospital Therapy, Occupational Diseases and Clinical Pharmacology», Medical Institute 677013, Yakutsk, 27 Oyunskogo Str
Vyacheslav Nikolaev
Yakutsk Scientific Center for Complex Medical Problems
Email: nikolaev1126@mail.ru
PhD in Biology, senior researcher at the Department of epidemiology of chronic noncommunicable diseases 677019, Yakutsk, 4 Sergelyakhskoe Highway
Efrosinya Efremova
E.N. Andreev Phthisiology Research and Practice Center
Email: efremovaen@tub.ykt.ru
phthisiatrician at the Department of patients with tuberculosis of the respiratory organs 677015, Yakutsk, 93 Petra Alekseeva Str
Alexandra Egorova
E.N. Andreev Phthisiology Research and Practice Center
Email: egorovaaa@tub.ykt.ru
phthisiatrician at the Department of patients with tuberculosis of the respiratory organs
Tatyana Tatarinova
Republican Clinical Hospital No. 3clinical pharmacologist at the Center for Predictive Medicine and Bioinformatics 677027, Yakutsk, 34 Kirova Str
Nadezhda Maksimova
Republican Clinical Hospital No. 3biologist at the Center for Predictive Medicine and Bioinformatics 677027, Yakutsk, 34 Kirova Str
Egor Prokopiev
E.N. Andreev Phthisiology Research and Practice Center
Email: ftiziatria-2010@mail.ru
director 677015, Yakutsk, 93 Petra Alekseeva Str
Alexander Kravchenko
E.N. Andreev Phthisiology Research and Practice Center
Email: kravchenkoaf@tub.ykt.ru
Dr. med. habil 677015, Yakutsk, 93 Petra Alekseeva Str
Olga Tatarinova
Republican Clinical Hospital No. 3
Email: guzrb3@yandex.ru
Dr. med. habil., chief physician 677027, Yakutsk, 34 Kirova Str
Alexander Vengerovsky
Siberian State Medical University of the Ministry of Healthcare
Email: pharm-sibgmu@rambler.ru
Dr. med. habil., professor, head of the Department of pharmacology 634034, Tomsk, 39 Uchebnaya Str
Dmitry Sychev
Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare
Email: rmapo@rmapo.ru
Dr. med. habil., professor, academician of RAS, rector 125445, Moscow, 38 Smol'naya Str
Әдебиет тізімі
- Khan S., Mandal R.K., Elasbali A.M. et al. Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: Trial sequence meta-analysis as evidence. Biosci Rep. 2019; 39(1): BSR20180845. https://dx.doi.org/10.1042/BSR20180845.
- Rens N.E., Uyl-de Groot C.A., Goldhaber-Fiebert J.D. et al. Cost-effectiveness of a pharmacogenomic test for stratified isoniazid dosing in treatment of active tuberculosis. Clin Infect Dis. 2020; 6: ciz1212. https://dx.doi.org/10.1093/cid/ciz1212.
- Imam F., Sharma M., Khayyam K.U. et al. Determination of isoniazid acetylation patterns in tuberculosis patients receiving DOT therapy under the Revised National tuberculosis Control Program (RNTCP) in India. Saudi Pharm J. 2020; 28(6): 641-47. https://dx.doi.org/10.1016/j.jsps.2020.04.003.
- Jarrar Y.B., Balasmeh A.A., Jarrar W. Sequence analysis of the N-acetyltransferase 2 gene (NAT2) among Jordanian volunteers. Libyan J Med. 2018; 13(1): 1408381. https://dx.doi.org/10.1080/19932820.2017.1408381.
- Suvichapanich S., Fukunaga K., Zahroh H. et al. NAT2 ultraslow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis. Pharmacogenet Genomics. 2018; 28(7): 167-76. https://dx.doi.org/10.1097/FPC.0000000000000339.
- Zhang M., Wang S., Wilffert B. et al. The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: A systematic review and meta-analysis. Br J Clin Pharmacol. 2018; 84(12): 2747-60. https://dx.doi.org/10.1111/bcp.13722.
- Metushi I., Uetrecht J., Phillips E. Mechanism of isoniazid-induced hepatotoxicity: then and now.Br J Clin Pharmacol. 2016; 81(6): 1030-36. https://dx.doi.org/10.1111/bcp.12885.
- Wang P., Pradhan K., Zhong X-bo, Ma X. Isoniazid metabolism and hepatotoxicity. Acta Pharm. 2016; 6(5): 384-92. https://dx.doi.org/10.1016/j.apsb.2016.07.014.
- Mthiyane T., Millard J., Adamson J. et al. N-acetyltransferase 2 genotypes among Zulu-speaking South Africans and isoniazid and N-acetyl-isoniazid pharmacokinetics during antituberculosis treatment. Antimicrob Agents Chemother. 2020; 64(4): e02376-19. https://dx.doi.org/10.1128/AAC.02376-19.
- Human NAT2 Alleles (Haplotypes). URL: http://nat.mbg.duth.gr/Human%20NAT2%20alleles_2013.htm (date of access - 04.04.2022).
- EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019; 70(6): 1222-61. https://dx.doi.org/10.1016/j.jhep.2019.02.014.
- Наследов А.Д. Профессиональный статистический анализ данных. С.-Пб: Питер. 2011: 400 с. ISBN: 978-5-459-00344-4.
- Kwon B.S., Kim Y., Lee S.H. et al. The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis. PLoS One. 2020; 15(7): e0236109. https://dx.doi.org/10.1371/journal.pone.0236109.
- Краснова Н.М., Евдокимова Н.Е., Егорова А.А. с соавт. Влияние типа ацетилирования на частоту гепатотоксичности изониазида у пациентов с впервые выявленным туберкулезом органов дыхания. Антибиотики и химиотерапия. 2020; 7-8: 31-36. https://dx.doi.org/10.37489/0235-2990-2020-65-7-8-31-36.
- Качанова А.А., Пименова Ю.А., Шуев ГН. с соавт. Изучение влияния полиморфных маркеров гена NAT2 на риск развития неже лательных реакций у пациентов с легочными формами туберкулеза, получавших изониазид и рифампицин. Безопасность и риск фармакотерапии. 2021; 1: 25-33. https://dx.doi.org/10.30895/2312-7821-2021-9-1-25-33.
- Combrink M., Loots D.T., du Preez I. Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin. Toxicol Lett. 2020; 322: 104-10. https://dx.doi.org/10.1016Zj.toxlet.2020.01.018.
- Jung J.A., Kim T.E., Lee H. et al. A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis. Drug Des Devel Ther. 2015; 9: 5433-38. https://dx.doi.org/10.2147/DDDT.S87131.
- Park J.S., Lee J.Y., Lee Y.J. et al. Serum levels of antituberculosis drugs and their effect on tuberculosis treatment outcome. Antimicrob Agents Chemother. 2015; 60(1): 92-98. https://dx.doi.org/10.1128/AAC.00693-15.
- Erwin E.R., Addison A.P., John S.F. et al. Pharmacokinetics of isoniazid: The good, the bad, and the alternatives. Tuberculosis (Edinb). 2019; 116S: S66-S70. https://dx.doi.org/10.1016/j.tube.2019.04.012.
- Pasipanodya J.G., McIlleron H., Burger A. et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013; 208(9): 1464-73. https://dx.doi.org/10.1093/infdis/jit352.
- Sileshi T., Tadesse E., Makonnen E. et al. The impact of first-line anti-tubercular drugs' pharmacokinetics on treatment outcome: A systematic review. Clin Pharmacol. 2021; 13: 1-12. https://dx.doi.org/10.2147/CPAA.S289714.
Қосымша файлдар
![](/img/style/loading.gif)